Merck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range Of Patients With Chronic Hepatitis C Virus Infection

Press/Media: Press / Media

PeriodApr 24 2015

Media coverage

1

Media coverage

  • TitleMerck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range Of Patients With Chronic Hepatitis C Virus Infection
    Media name/outletTheStreet.com
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz